openPR Logo
Press release

Fabry Disease Market to be at Forefront by 2023

04-16-2018 08:58 PM CET | Health & Medicine

Press release from: Transparency Market Research

Fabry disease is an unusual, life-threatening situation with debilitating condition. Fabry disease is an uncommon X-linked inherited disorder. It is caused by the lack of the enzyme alpha galactosidase-A (a-GAL A). It is initiated by the absence of enzyme required to metabolize the lipids, fat-like substances like waxes, oils, and fatty acids. This disease is also known as alpha-galactosidase-A deficiency. Often there is a complete deficiency of a-Gal results in a severe form called the classic Fabry disease.

This classic form mostly affects male.Symptoms of this disorder usually appear during childhood or adolescence in both male and female which includes pain that can be either full body or localized known as pricking sensation or numbness (acroparesthesia), gastro hyperactivity, burning sensation in hands, renal inefficiency, cardiac problem and cloudiness of cornea. The pain that is caused by the disease can be treated with anticonvulsants like phenytoin and carbamazepine. Gastric hyperactivity is treated by metoclopramide. Some patient may require dialysis or kidney replacement. However, restricting diet does not help to reduce lipid buildup in cells. The incidence of Fabry disease affects approximately 1 in 40,000 to 60,000 males. Occurrence of this disorder is less frequent in females.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=9515

Fabry Disease Market can be segmented on the basis of its treatment and geography. The type of treatment can be classified as Enzyme replacement therapy (ERT), Alternative therapies and Emergency treatment strategy. ERT has been available for the treatment of Fabry disease since 2001. U.S Food and Drug Administration has approved the ERT for the treatment of Fabry disease. ERT comforts the pain, decreases the lipid storage and preserves organ function in patients with this disorder. Alternative therapy involves palliative and supportive approach for the treatment of Fabry disease. Emergency treatment strategy involves administration of small molecule drugs which are very effective and have a quick response.

The Fabry disease market presents an enormous opportunity in its treatment and cure. The driving factors those have been aiding the growth of The Global Fabry Disease Market. Firstly, there are provision for orphan drugs, diseases with restricted patient population, such as Fabry disease have limited approved drugs. Special benefits are given to this drugs like few years of market exclusivity, tax benefits for clinical testing and exclusion from prescription drug fees in order to recover the research and development expenses of the drug.

Request to View ToC of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=9515

Secondly, use of tools like ICD, it is a standard tool for diagnosis purposes. These codes are used for reimbursements by the private organizations or government insurers. The code for Fabry disease is E75.21 ICD-10-CM code. ICD-10 codes have been designed to provide superior specificity and better clinical details. ICD-10-CM codes are also expected to provide complete healthcare data, thus helping in the development of advanced clinical pathways and disease protocols. However, currently there is a lack of disease-modifying therapy in the Fabry disease market but there are lot of potential for the improvement in near future.

Some of the key players in this market are Genzyme Corporation, Shire plc. Amicus Therapeutics. Inc., Synageva BioPharma Corp., JCR Pharmaceutical, ISU ABXIS Co. Ltd., Protalix BioTherapeutics, and Neuraltus Pharmaceuticals, Inc., Biosidus.

View Report -

https://www.transparencymarketresearch.com/fabry-disease-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Fabry Disease Market to be at Forefront by 2023 here

News-ID: 1018630 • Views: 284

More Releases from Transparency Market Research

Electron Multiplier Market Poised to Expand at a Robust Pace Over 2021-2031
Transparency Market Research delivers key insights on the global electron multiplier market. In terms of revenue, the global electron multiplier market is estimated to expand at a CAGR of 3.8% during the forecast period, owing to numerous factors, regarding which TMR offers thorough insights and forecasts in its report on the global electron multiplier market. Get report details-https://www.transparencymarketresearch.com/electron-multipliers-market.html The global electron multiplier market is broadly affected by several factors, including rise in
Exfoliating Gloves/Mitts Market Is likely to register double digit CAGR during 2 …
Exfoliating Gloves Market: Introduction Exfoliating gloves are usually made from a roughly textured fabric that helps remove dead skin and excess dirt and oil, when rubbed against the skin. Exfoliating the body and face with gloves provides even skin tone and increases the cells, which give the consumer polished, glowing, and vibrant skin. Exfoliating gloves also help lock the moisture of dry and itchy skin. Exfoliating gloves are available in natural
Luxury Handbag Market Estimated to Experience a Hike in Growth by 2022-2031
Luxury Handbag Market has been published by Transparency Market Research (TMR). It presents a wealth of information on key market dynamics, including drivers, market trends, and challenges, as well as the structure of the global luxury handbag market. TMR's study offers valuable information about the global luxury handbag market to illustrate how the Luxury Handbag Market would grow during the forecast period, 2021 - 2031. Get report details-https://www.transparencymarketresearch.com/luxury-handbag-market.html Key indicators of market
Liquid Car Care Market Foreseen to grow exponentially over 2021-2031
According to the report, the liquid car care market in Europe is projected to surpass EUR 7.7 Bn by 2031, expanding at a CAGR of 1.80% during the forecast period. Liquid car care products are developed for cleaning exterior and interior trims and body parts of cars. Liquid car care involves cleaning, washing, polishing, waxing, coating, and sealing the glaze of the car, which protects it from corrosion and other

All 5 Releases


More Releases for Fabry

Fabry Disease - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Fabry Disease - Pipeline Review, H2 201 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H2 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape. Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called
Fabry Disease Market show exponential growth by 2023
Fabry disease is an unusual, life-threatening situation with debilitating condition. Fabry disease is an uncommon X-linked inherited disorder. It is caused by the lack of the enzyme alpha galactosidase-A (a-GAL A). It is initiated by the absence of enzyme required to metabolize the lipids, fat-like substances like waxes, oils, and fatty acids. This disease is also known as alpha-galactosidase-A deficiency. Often there is a complete deficiency of a-Gal results in a severe form
Fabry Disease Market | Analysis & Key Trends 2023
Fabry disease is an unusual, life-threatening situation with debilitating condition. Fabry disease is an uncommon X-linked inherited disorder. It is caused by the lack of the enzyme alpha galactosidase-A (a-GAL A). It is initiated by the absence of enzyme required to metabolize the lipids, fat-like substances like waxes, oils, and fatty acids. This disease is also known as alpha-galactosidase-A deficiency. Often there is a complete deficiency of a-Gal results in
Fabry Disease - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Fabry Disease - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H1 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape. Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called
Worldwide Fabry Disease Market Report 2016-2026
Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease is known to cause variety of systemic symptoms and complications, one of
Market Intelligence Report Fabry Disease, 2016-2026
Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease is known to cause variety of systemic symptoms and complications, one of